pioglitazone has been researched along with msdc-0160 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Colca, JR; Fisher, RM; Kletzein, RF; Parker, TT; Tanis, SP | 1 |
| Adams, WJ; Artman, GD; Colca, JR; Gadwood, RC; Kletzien, RF; Larsen, SD; Lee, PH; McDonald, WG; Parker, TT; Tanis, SP; Zeller, JB | 1 |
| Adams, WJ; Colca, JR; Liang, J; McDonald, WG; Orloff, DG; Shashlo, A; VanderLugt, JT; Zhou, R | 1 |
1 trial(s) available for pioglitazone and msdc-0160
| Article | Year |
|---|---|
Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer.
Topics: Adiponectin; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Edema; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Mitochondrial Proteins; Pioglitazone; Pyridines; Thiazolidinediones | 2013 |
2 other study(ies) available for pioglitazone and msdc-0160
| Article | Year |
|---|---|
Synthesis and biological activity of metabolites of the antidiabetic, antihyperglycemic agent pioglitazone.
Topics: Animals; Dogs; Half-Life; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Mice; Pioglitazone; Rats; Thiazoles; Thiazolidinediones | 1996 |
PPARĪ³-sparing thiazolidinediones as insulin sensitizers. Design, synthesis and selection of compounds for clinical development.
Topics: Dose-Response Relationship, Drug; Drug Design; Humans; Insulin Resistance; Molecular Structure; PPAR gamma; Structure-Activity Relationship; Thiazolidinediones | 2018 |